Re­call re­port: Fre­se­nius Kabi yanks in­flam­ma­to­ry med Ke­toro­lac af­ter find­ing par­tic­u­lates in vials

The FDA on Fri­day an­nounced that Fre­se­nius Kabi USA, based in Illi­nois, vol­un­tar­i­ly re­called a sin­gle lot of Ke­toro­lac Tromethamine In­jec­tion USP 30 mg/mL. Par­tic­u­late mat­ter was found in re­serve sam­ple vials of the drug, which is used as a short-term med­ica­tion to man­age se­vere acute pain which re­quires anal­ge­sia at the opi­oid lev­el.

Fre­se­nius Kabi USA has re­ceived no re­ports of neg­a­tive side ef­fects from the lot, the FDA said in a re­lease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.